Leslie B Gordon1, Joe Massaro2, Ralph B D'Agostino2, Susan E Campbell2, Joan Brazier2, W Ted Brown2, Monica E Kleinman2, Mark W Kieran2. 1. From the Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI (L.B.G.); Department of Anesthesia, Division of Critical Care Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA (L.B.G., M.E.K.); Department of Mathematics and Statistics, Boston University, Harvard Clinical Research Institute, Boston, MA (J.M., R.B.D.); Center for Gerontology and Health Care Research, Brown University, Providence, RI (S.E.C., J.B.); Department of Genetics, New York State Institute for Basic Research, Staten Island, NY (W.T.B.); Hematology-Oncology, Boston Children's Hospital, Division of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (M.W.K.). Leslie_Gordon@brown.edu. 2. From the Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI (L.B.G.); Department of Anesthesia, Division of Critical Care Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA (L.B.G., M.E.K.); Department of Mathematics and Statistics, Boston University, Harvard Clinical Research Institute, Boston, MA (J.M., R.B.D.); Center for Gerontology and Health Care Research, Brown University, Providence, RI (S.E.C., J.B.); Department of Genetics, New York State Institute for Basic Research, Staten Island, NY (W.T.B.); Hematology-Oncology, Boston Children's Hospital, Division of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (M.W.K.).
Abstract
BACKGROUND: Hutchinson-Gilford progeria syndrome is an ultrarare segmental premature aging disease resulting in early death from heart attack or stroke. There is no approved treatment, but starting in 2007, several recent single-arm clinical trials administered inhibitors of protein farnesylation aimed at reducing toxicity of the disease-producing protein progerin. No study assessed whether treatments influence patient survival. The key elements necessary for this analysis are a robust natural history of survival and comparison with a sufficiently large patient population that has been treated for a sufficient time period with disease-targeting medications. METHODS AND RESULTS: We generated Kaplan-Meier survival analyses for the largest untreated Hutchinson-Gilford progeria syndrome cohort to date. Mean survival was 14.6 years. Comparing survival for treated versus age- and sex-matched untreated cohorts, hazard ratio was 0.13 (95% confidence interval, 0.04-0.37; P<0.001) with median follow-up of 5.3 years from time of treatment initiation. There were 21 of 43 deaths in untreated versus 5 of 43 deaths among treated subjects. Treatment increased mean survival by 1.6 years. CONCLUSIONS: This study provides a robust untreated disease survival profile that can be used for comparisons now and in the future to assess changes in survival with treatments for Hutchinson-Gilford progeria syndrome. The current comparisons estimating increased survival with protein farnesylation inhibitors provide the first evidence of treatments influencing survival for this fatal disease. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique Indentifiers: NCT00425607, NCT00879034, and NCT00916747.
BACKGROUND:Hutchinson-Gilford progeria syndrome is an ultrarare segmental premature aging disease resulting in early death from heart attack or stroke. There is no approved treatment, but starting in 2007, several recent single-arm clinical trials administered inhibitors of protein farnesylation aimed at reducing toxicity of the disease-producing protein progerin. No study assessed whether treatments influence patient survival. The key elements necessary for this analysis are a robust natural history of survival and comparison with a sufficiently large patient population that has been treated for a sufficient time period with disease-targeting medications. METHODS AND RESULTS: We generated Kaplan-Meier survival analyses for the largest untreated Hutchinson-Gilford progeria syndrome cohort to date. Mean survival was 14.6 years. Comparing survival for treated versus age- and sex-matched untreated cohorts, hazard ratio was 0.13 (95% confidence interval, 0.04-0.37; P<0.001) with median follow-up of 5.3 years from time of treatment initiation. There were 21 of 43 deaths in untreated versus 5 of 43 deaths among treated subjects. Treatment increased mean survival by 1.6 years. CONCLUSIONS: This study provides a robust untreated disease survival profile that can be used for comparisons now and in the future to assess changes in survival with treatments for Hutchinson-Gilford progeria syndrome. The current comparisons estimating increased survival with protein farnesylation inhibitors provide the first evidence of treatments influencing survival for this fatal disease. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique Indentifiers: NCT00425607, NCT00879034, and NCT00916747.
Authors: Fuki M Hisama; Davor Lessel; Dru Leistritz; Katrin Friedrich; Kim L McBride; Matthew T Pastore; Gary S Gottesman; Bidisha Saha; George M Martin; Christian Kubisch; Junko Oshima Journal: Am J Med Genet A Date: 2011-11-07 Impact factor: 2.802
Authors: Marie Gerhard-Herman; Leslie B Smoot; Nicole Wake; Mark W Kieran; Monica E Kleinman; David T Miller; Armin Schwartzman; Anita Giobbie-Hurder; Donna Neuberg; Leslie B Gordon Journal: Hypertension Date: 2011-11-14 Impact factor: 10.190
Authors: Leslie B Gordon; Monica E Kleinman; David T Miller; Donna S Neuberg; Anita Giobbie-Hurder; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert Cleveland; Brian D Snyder; Brian Fligor; W Robert Bishop; Paul Statkevich; Amy Regen; Andrew Sonis; Susan Riley; Christine Ploski; Annette Correia; Nicolle Quinn; Nicole J Ullrich; Ara Nazarian; Marilyn G Liang; Susanna Y Huh; Armin Schwartzman; Mark W Kieran Journal: Proc Natl Acad Sci U S A Date: 2012-09-24 Impact factor: 11.205
Authors: Marc A Pfeffer; Anthony Keech; Frank M Sacks; Stuart M Cobbe; Andrew Tonkin; Robert P Byington; Barry R Davis; Carola P Friedman; Eugene Braunwald Journal: Circulation Date: 2002-05-21 Impact factor: 29.690
Authors: Shao H Yang; Margarita Meta; Xin Qiao; David Frost; Joy Bauch; Catherine Coffinier; Sharmila Majumdar; Martin O Bergo; Stephen G Young; Loren G Fong Journal: J Clin Invest Date: 2006-08 Impact factor: 14.808
Authors: Craig F Munns; Mansoor H Rajab; Janet Hong; Julie Briody; Wolfgang Högler; Mary McQuade; David G Little; Christopher T Cowell Journal: Bone Date: 2007-05-13 Impact factor: 4.398
Authors: Nicole J Ullrich; Mark W Kieran; David T Miller; Leslie B Gordon; Yoon-Jae Cho; V Michelle Silvera; Anita Giobbie-Hurder; Donna Neuberg; Monica E Kleinman Journal: Neurology Date: 2013-06-28 Impact factor: 9.910
Authors: Stavit A Shalev; Annachiara De Sandre-Giovannoli; Ayelet Adir Shani; Nicolas Levy Journal: Am J Med Genet A Date: 2007-08-15 Impact factor: 2.802
Authors: Paul T Arsenovic; Iswarya Ramachandran; Kranthidhar Bathula; Ruijun Zhu; Jiten D Narang; Natalie A Noll; Christopher A Lemmon; Gregg G Gundersen; Daniel E Conway Journal: Biophys J Date: 2016-01-05 Impact factor: 4.033
Authors: Leslie B Gordon; Monica E Kleinman; Joe Massaro; Ralph B D'Agostino; Heather Shappell; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert H Cleveland; Ara Nazarian; Brian D Snyder; Nicole J Ullrich; V Michelle Silvera; Marilyn G Liang; Nicolle Quinn; David T Miller; Susanna Y Huh; Anne A Dowton; Kelly Littlefield; Maya M Greer; Mark W Kieran Journal: Circulation Date: 2016-07-12 Impact factor: 29.690
Authors: Michael R Erdos; Wayne A Cabral; Urraca L Tavarez; Kan Cao; Jelena Gvozdenovic-Jeremic; Narisu Narisu; Patricia M Zerfas; Stacy Crumley; Yoseph Boku; Gunnar Hanson; Dan V Mourich; Ryszard Kole; Michael A Eckhaus; Leslie B Gordon; Francis S Collins Journal: Nat Med Date: 2021-03-11 Impact factor: 53.440
Authors: Graham F Brady; Raymond Kwan; Juliana Bragazzi Cunha; Jared S Elenbaas; M Bishr Omary Journal: Gastroenterology Date: 2018-03-13 Impact factor: 22.682